It is understood that diseases can arise as a result of alteration in genes that affect activity within the cell. Disease states can be modeled by using the "cre-recombinase" (Cre) to induce the specific transformation of genes from the "normal" to the "mutant" state. But, for Cre to work and create the change, it must be expressed in the appropriate cell types at the correct time during development.
Unfortunately, there is a critical shortage of Cre resources needed to perform these types of studies. This new international project will create more mutant genes, and will also address the shortage of Cre resources. EU scientists will create Cre resources for a wide variety of organs, while BC scientists will create resources for the brain, eye, and spinal cord, adding to and building on the province's existing strengths.
This project may ultimately generate advances in medical therapy for a host of neurological conditions. This invaluable information will not only speed up research and discovery, both academically and commercially, but also draws investment to and stimulates commercial activities in British Columbia.
"Not only is this project a showcase for British Columbia's brain research expertise, but a major international collaboration that really demonstrates the generosity and enthusiasm of researchers around the globe. The outcomes of this project will be truly internationally available enabling tools and we are very proud to play an important role in their development" says Dr. Alan Winter, President & CEO of Genome BC.
Genome BC has funded this project as part of its Applied Genomics Consortium Program, which brings together national and international consortia, funding partners and industry and will provide an opportunity to fund projects that will have a significant impact on strategic sectors of British Columbia's economy.
|Contact: Jenny Boon|